A recent study suggests that patients who discontinue new slimming jabs like Mounjaro or Wegovy may regain reduced body mass far faster than those who halt conventional diet and exercise programs.
Research printed in a prominent medical journal shows that while overweight individuals often shed substantial amounts of their body weight while using the jabs, the weight comes back at an average rate of nearly a kilo each month once they quit.
"People purchasing such drugs should be aware of the potential of rapid weight regain when the treatment concludes," stated expert Dr. Susan Jebb.
This pace of recovery implies a reversion to original mass in about 18 months.
Comparing Therapies
The analysis, which reviewed dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with older methods.
Scientists point out that people who shed pounds through diet and exercise typically see a slower weight regain—around 100 grams monthly—after stopping.
Understanding the Quick Regain
Nutrition scientists believe the way of the drugs accounts for the accelerated regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Artificially providing the hormone concentrations far above than normal could lead to the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement leads to hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
The NHS recommend the jabs for individuals with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the treatment might need to be life-long.
This view is reinforced by drug manufacturers, who note that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
User Testimonies
Individuals who have discontinued the jabs explain a intense resurgence of appetite.
"It felt as if a trigger flipping and you're instantly ravenous," said one woman.
This challenge is compounded if users have not established permanent dietary or behavioural changes during therapy.
Significant Interest
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is more common among females compared to men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Finally, experts caution that while GLP-1 drugs are potent agents for weight loss, they are not a permanent solution and maintained weight loss hinges on combined behavioural support.
